Inhibitory effect of anti-hepatitis drug bicyclol on invasion of human hepatocellular carcinoma MHCC97-H cells with high metastasis potential and its relative mechanisms

Journal of Asian Natural Products Research

Volumn 11, Issue 6, 2009, Pages 576-583

  Sun, Hua ^a   Liu, Geng Tao ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Bicyclol; Human hepatocellular carcinoma; Invasion; Metastasis; MHCC97 H cell

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BICYCLOL; FIBRONECTIN; LAMININ; MESSENGER RNA; NITROBLUE TETRAZOLIUM; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL ASSAY; CELL INVASION; CELL STRAIN; CELL STRAIN MHCC97 H; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

ALPHA-FETOPROTEINS; BIPHENYL COMPOUNDS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; HEPATITIS; HUMANS; LIVER NEOPLASMS; MOLECULAR STRUCTURE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR CELLS, CULTURED; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449625296     PISSN: 10286020     EISSN: 14772213     Source Type: Journal    
DOI: 10.1080/10286020902942368     Document Type: Article

References (18)

1. P.P. Michielsen, S.M. Francque, and J.L. Van Dongen, World J. Surg. Oncol. 3, 27 (2005).
2. Y. Li, G.W. Dai, Y. Li, and G.T. Liu, Acta Pharm. Sin. 36, 723 (2001).
3. G.T. Liu, C.Z. Zhang, Y. Li, H.L. Wei, and W. Hu, Chin. Med. Sci. J. 14, 51 (1999).
4. M. Li andG.T. Liu,World J.Gastroenterol. 10, 1775 (2004).
5. D.M. Zhao and G.T. Liu, Natl Pharm. Assoc. J. 81, 844 (2001).
6. H. Lu and Y. Li, Acta Pharmacol. Sin. 23, 942 (2002).
7. H. Sun and G.T. Liu, Cancer Lett. 236, 239 (2006).
8. L.M. Yerian, R.A. Anders, M. Tretiakova, and J. Hart, Am. J. Surg. Pathol. 28, 357 (2004).
9. T. Mosmann, J. Immunol. Methods 65, 55 (1983).
10. R. Han, Research and development of anticancer drugs and experimental techniques (Beijing Medical University and Chinese Xiehe Medical University Press, Beijing, 1997), pp. 353-356.
11. J. Tian, Z.Y. Tang, and S.L. Ye, Chin. J. Oncol. 20, 405 (1998).
12. P.S. Steeg, G. Bevilacqua, L. Kopper, U.P. Thorgeirsson, J.E. Talmadge, L.A. Liotta, and M.E. Sobel, J. Natl Cancer Inst. 80, 200 (1988).
13. Z.B. Wei, Y.L. Wu, and Z.K. Zhai, Chin. J. Oncol. 19, 378 (1997).
14. Y.F. Lu, J.L. Lin, and M.Y. Wei, Chin. J. Bases Clin. Gen. Surg. 7, 241 (2000).
15. J. Tian, Z.Y. Tang, and Q. Cai, Natl Pharm. Assoc. J. 79, 470 (1999).
16. D.F. Yao, X.H. Wu, Y. Zhu, G.S. Shi, Z.Z. Dong, D.B. Yao, W. Wu, L.W. Qiu, and X.Y. Meng, Hepatobiliary Pancreat. Dis. Int. 4, 220 (2005).
17. F. Blasi, Bioassays 15, 105 (1993).
18. D. Bader, A. Riskin, O. Vafsi, A. Tamir, B. Peskin,N. Israel, R.Merksamer, H.Dar, and M. David, Clin. Chim. Acta 349, 15 (2004).